Report for the third quarter of 2024 of Harbin Pharmaceutical Group Co., Ltd.

SZSIOct 26 00:00 · Announcements

Harbin Pharmaceutical Group (600664.SH): net income of 0.508 billion yuan in the first three quarters, a year-on-year increase of 74.97%.

Gelonghui, October 25th - Harbin Pharmaceutical Group (600664.SH) announced its third-quarter report, with revenue for the first three quarters at 12.256 billion yuan, a year-on-year increase of 6.63%, net income of 0.508 billion yuan, a year-on-year increase of 74.97%, non-GAAP net income of 0.47 billion yuan, a year-on-year increase of 91.39%, and basic earnings per share of 0.20 yuan.

Gelonghui FinanceOct 25 16:21

Harbin Pharmaceutical Group (600664.SH) released its performance for the first three quarters, with a net income of 0.508 billion yuan, a year-on-year increase of 74.97%.

Harbin Pharmaceutical Group (600664.SH) released the quarterly report for the first three quarters of 2024, during the reporting period the company achieved revenue...

Zhitong FinanceOct 25 16:12

Harbin Pharmaceutical Group (600664.SH): Currently, there are no traditional Chinese medicine milk tea products.

Harbin Pharmaceutical Group (600664.SH) stated on the investor interaction platform on September 5th that the company has products such as traditional Chinese medicine decoction pieces and protein powder, but currently does not have any traditional Chinese medicine milk tea products.

Gelonghui FinanceSep 5 17:42

Hainan Pharmaceutical Group Co., Ltd. 2024 Semi-Annual Report

SZSIAug 23 00:00 · Announcements

哈药集团股份有限公司2024年半年度报告_摘要

SZSIAug 23 00:00 · Announcements